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Abstract. CD33 is a myeloid-associated marker and belongs to the sialic acid-binding immuno-
globulin (Ig)-like lectin (Siglec) family. Such types of receptors are highly expressed in acute myeloid 
leukemia, which could be used in its treatment. CD33 shows high variability in its expression levels 
with still unknown reasons. Here, we investigated the CD33 expression of monocytes in human blood 
samples processed at different temperatures and in dependence on their phagocytic activity against 
opsonized Escherichia coli. The samples were stained by fluorescently labelled anti-human CD14 to 
specify the monocyte population, anti-human CD33 antibodies to evaluate CD33 expression and 
analyzed by flow cytometry and confocal laser scanning microscopy. In blood samples kept at 37°C 
or first pre-chilled at 0°C with subsequent warming up to 37°C, the percentage of CD33-positive 
monocytes as well as their relative fluorescence intensity was up-regulated compared to samples kept 
constantly at 0°C. After exposure to E. coli the CD33 relative fluorescence intensity of the monocytes 
activated at 37°C was 3 to 4 times higher than that of those cells kept inactive at 0°C. Microscopic 
analysis showed internalisation of CD33 due to its enhanced expression on the surface followed by 
engulfment of E. coli. 
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Introduction
Clusters of differentiation (CDs) are receptors or surface 
markers used to classify cell type and maturation stage of 
leukocytes as well as other associated cells by staining with 
specific antibodies. CD antigens as receptors and ligands 
accomplish a  variety of critical functions in the immune 
response such, cell signal cascades and cell adhesion (Zola 
et al. 2007). In certain circumstances CD antigens are ex-
pressed in some specific developmental stage or under some 
environmental and experimental conditions with different 
expression level. Consequently, the patterns of expression of 
cell surface CD antigens are promising goals for diagnostic 
and therapeutic clinical applications and research of differ-
ent types of diseases such as cardiovascular disease, cancer, 
immunotherapy, and drug targeting (Golay et al. 2000; 
Woolfson et al. 2006; Sakamoto et al. 2009).
CD33, a  67 kDa type I  transmembrane cell surface 
glycoprotein receptor, belongs to the sialic acid-binding 
immunoglobulin-like lectins (Siglecs, Siglec-3) family. 
Structurally, CD33 contains a V-set domain, a C2-set do-
main, and a  transmembrane region followed by immu-
noreceptor tyrosine-based inhibitory motif (ITIM) and 
ITIM-like motif (Laszlo et al. 2014a). CD33 is expressed 
at high level on monocytes and macrophages, but at low 
level on mature granulocytes (Andrew et al. 1983; Freeman 
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et al. 1995). Besides, CD33 is an accepted surface marker 
to identify monocytes (Terstappen et al. 1990). However, 
despite the crucial role of CD33, little is known about its 
function in myeloid cells, except that it may acts as an in-
hibitory molecule on the innate immune cells to mediate 
the cell–cell interaction and to inhibit normal functions 
through a reducing effect on tyrosine kinase-driven sign-
aling (Paul et al. 2000; Crocker and Redelinghuys 2008). 
Recent studies have shown that antibodies specific to 
CD33 possessed an ability to activate cytokine secretion by 
monocytes, suggesting a potential role of CD33 molecule 
in the cytokine responses of the immune system (Lajaunias 
et al. 2005). In addition, it has been noted that CD33 acts 
as an inhibitory factor on dendritic cell differentiation 
(Ferlazzo et al. 2000). Dendritic cells are antigen present-
ing cells which mainly interact with the adaptive immune 
system whereas monocyte derived macrophages are part 
of the innate immune response. CD33 up-regulation might 
inhibit dendritic cell differentiation when faced with a high 
number of pathogens (such as opsonized bacteria) to 
ensure the availability of these cells for phagocytosis and 
elimination of these pathogens. Previous studies have also 
shown that up-regulation of CD33 in chronic obstructive 
pulmonary disease (COPD) patients was higher than that 
in the normal control group; however, no statistically sig-
nificant differences were found between control group and 
patients (Zhang et al. 2013). 
Moreover, the knowledge of CD33 expression levels could 
offer promising therapeutic strategies for certain diseases. 
Previous studies reported a correlation between the expres-
sion of CD33 and Alzheimer’s disease and that the inhibition 
of CD33 may be a promising therapeutic target for this dis-
ease (Jiang et al. 2014; Hooli and Tanzi 2016). Furthermore, 
the level of CD33 has been shown to be associated with the 
disease prognostic factors for acute myeloid leukemia (AML) 
and may thus serve as an attractive candidate for antibody-
based therapeutic (Cowan et al. 2013; Krupka et al. 2014; 
Laszlo et al. 2014b). 
It is well established that several factors such as purifica-
tion methods, storage and incubation temperature, or speci-
men age and anticoagulants affect the antigen expression 
levels of certain cell surface proteins of leukocytes. Some 
leukocyte surface markers (CD11a,b,c, CD18 and CD35) 
can be increased by handling procedures and temperature 
changes (Fearon and Collins 1983; Miller et al. 1987; Forsyth 
and Levinsky 1990; Lundahl et al. 1995), whereas these fac-
tors have no effect on other antigens for example CD15s, 
CD44, or CD62L (Youssef et al. 1995). Nevertheless, it was 
also reported that preparation procedure at higher tempera-
ture decreased the expression of CD62L (Stibenz et al. 1994; 
Lundahl et al. 1995).
Some studies found that besides temperature, phago-
cytosis may also influence the expression of antigens, 
suggesting that these changes may be caused by inflamma-
tion due to immunological response following phagocytic 
activity. For instance, the expression of CD11b and CD35 
is increased (Repo et al. 1995), while CD64 and CD88 were 
not altered (Furebring et al. 2004) but CD14 is decreased 
in lipopolysaccharide (LPS)-stimulated monocytes (Jor-
gensen et al. 2001). Hence, the knowledge about up- or 
down-regulation of surface markers might be useful for 
therapeutic concepts. 
To date, only a few research reports give detailed infor-
mation on sample handling for the investigation of CD33 
expression. The influence of temperature and phagocytosis 
on up- or down-regulation of CD33 expression should be 
clearly understood to support existing or future diagnostic 
and therapeutic approaches. Therefore, in the current study 
we investigated the effect of temperature as well as the 
presence of phagocytosis activating agents, E. coli, on the 
expression level of monocytes. 
Materials and Methods 
Materials
Phosphate buffered saline (PBS) pH 7.4 stock solution 
(10×) was purchased from Fisher Scientific (Pittsburgh, 
PA). NH4Cl, NaHCO3, EDTA were purchased from Sigma. 
PerCP/Cyanine5.5 anti-human CD33 Antibody, Mouse 
IgG1, κ, clone WM53 and clone P67.6 were purchased from 
BioLegend (San Diego, CA). Isotype control (non-specific 
isotype control antibody) PerCP/Cyanine5.5 Mouse IgG1, 
κ, Isotype Ctrl Antibody was purchased from BioLegend 
(San Diego, CA). Alexa Fluor® 488 anti-human CD14 anti-
body (Clone M5E2) was purchased from BD Pharmingen 
(San Diego, CA). Lithium heparin vacutainers (34 I.U.) 
were purchased from Becton Dickinson (Plymouth, UK). 
PhagotestTM and PhagoburstTM kit were purchased from 
Glycotope-Biotechnology (Heidelberg, Germany). All 
chemicals used for experimental work were of analytical 
grade.
Blood collection, preparation and leukocyte staining
Freshly withdrawn venous blood anticoagulated by lithium 
heparin was collected from healthy volunteers. Informed 
consent was obtained from all donors in written form. The 
blood samples were withdrawn in accordance with the trans-
fusion law of Germany. The use of donor blood samples for 
scientific purposes was approved by the ethics committee of 
the Charité – Universitätsmedizin Berlin (# EA1/137/14). 
Two tubes of blood were collected at the same time: one sam-
ple was immediately transferred to an ice bath (0°C), and the 
other sample was taken into a water bath and kept at 37°C. 
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Figure 1 shows the experimental design. The samples were 
handled in three different ways. Whole blood was aliquoted 
into 50  µl samples in three separate tubes. One tube was 
maintained always on ice (0°C). A second tube was chilled 
for 10 min at 0°C and then transferred to a water bath for 
10 min at 37°C. The third tube was placed immediately and 
maintained in the water bath at 37°C.
At the end of the incubation period, all samples were 
placed in the ice-bath, and washed with ice-cold PBS. The 
cells were re-suspended and then incubated with anti-CD14 
and anti-CD33 antibody using concentrations suggested 
by the manufacturer with a concentration of 16 µg/ml for 
30  min at 0°C in darkness. Erythrocytes were lysed with 
ammonium chloride solution (155  mM NH4Cl, 12  mM 
NaHCO3, 0.1 mM EDTA) for 15 min. The cells were washed 
twice and re-suspended in ice-cold PBS and then immedi-
ately analysed by flow cytometry
Phagocytosis of bacteria at different temperatures
Phagocytosis of non-labeled E. coli
Opsonized E. coli (1–2 × 109 bacteria per ml, Phagoburst 
kitTM) was used to examine the engulfment of bacteria. The 
samples were handled in the same way as in the temperature 
experiments. One tube was maintained always on ice the 
other tube was pre-chilled for 10 min and then transferred 
from the ice bath to the water bath (37°C) and warmed up for 
10 min at 37°C after adding 10 µl of non-labeled opsonized 
E. coli. In parallel, the samples kept at 37°C were incubated 
for 10 min with 10 µl of E. coli.
After 10 min, engulfment and uptake were stopped by cool-
ing to 0°C and washing with ice cold PBS. Subsequently, cells 
were stained with anti-CD14 and anti-CD33 antibody with 
a concentration of 16 µg/ml for 30 min at 0°C in darkness, 
followed by erythrocyte lysis using ammonium chloride lys-
ing solution for 15 min. Cells were washed and re-suspended 
in PBS and immediately analysed with the flow cytometer. 
Phagotest of Fluorescein isothiocyanate (FITC)-labeled 
opsonized E. coli
PhagotestTM kit was used to confirm healthy phagocytotic 
activity of monocytes. Manufacturer’s instructions were 
partially modified: all reactions were performed with half 
of the volume, samples were incubated at two different 
temperature conditions, lysing solution was changed to am-
monium chloride lysing solution, and DNA was not stained.
Internalisation of CD33 during phagocytosis
To examine the internalisation of CD33, 50 µl of blood were 
mixed with anti-CD14 and anti-CD33 antibody with a final 
staining concentration of 16 µg/ml for 30 min at 0°C in dark-
ness. Then 10 µl opsonised E. coli (1–2 × 109 bacteria per ml) 
was added and incubated at 37°C or an ice bath (0°C) for 
negative controls for 10 min. 
After 10 min, engulfment and uptake were stopped by 
cooling to 0°C and washing with ice cold PBS. Subsequently, 
ammonium chloride lysing solution was added and incu-
bated on ice for 15 min. Cells were washed and re-suspended 
in PBS and immediately analysed with the flow cytometry.
Flow cytometry
The leukocytes were analysed by flow cytometry (FACS-
Canto II, Becton and Dickinson, Franklin Lakes, NJ, U.S.A.) 
after diluting in PBS with ratio of 1:40 (Tölle et al. 2010; Zhao 
et al. 2017). 10,000 total events from each tube were collected. 
Monocytes, granulocytes, and lymphocytes were identiﬁed 
based on their forward and sideward scatter (FSC and SSC, 
resp.) characteristics. Then, the additional staining with 
anti-CD14 was gated out to identify monocyte population. 
Subsequently, positively stained CD33 cells were determined 
in the PerCP/Cy5.5 fluorescence channel as relative median 
fluorescence intensity (RFI). Data were analysed using the 
FlowJo v10 software (Tree Star, Ashland, OR). 
Figure 1. Schematic experimental design. Two sets of three tubes 
with whole blood from the test subject were handled as followed: 
two 50 µl aliquots of whole blood from ice bath (0°C) cooler were 
either maintained always on ice or after pre-chilling warmed up 
to 37°C. One 50 µl aliquot of whole blood from water bath (37°C) 
was always prepared throughout at 37°C. 
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Confocal laser scanning microscopy (CLSM)
Non-labeled (control), anti-CD14, and anti-CD33 labeled 
samples were investigated using a confocal laser scanning 
microscope (CLSM; ZeissLSM 510 meta, Zeiss MicroImag-
ing GmbH, Jena, Germany) equipped with a 100× oil immer-
sion objective, with a numerical aperture of 1.3. Images of 
the samples were prepared in transmission and fluorescence 
mode with fluorescence excitation at 488 nm for both FITC 
as well as PerCP/Cy5.5, a band pass filter (513–556 nm) for 
FITC emission and a 650 nm long pass emission filter for 
PerCP/Cy5.5. Cells stained with anti-CD33 and anti-CD14 
antibodies were identified as monocytes. The fluorescence 
distribution inside the monocytes before and after stimu-
lation with E. coli was investigated by analysis of z-stacks 
applying the LSM 510 software.
Statistical analysis
Analyses and graphs were performed using GraphPad Prism 
6 software (GraphPad, San Diego, CA). Statistical analysis was 
performed using one-way analysis of variance followed by the 
Tukey multiple comparison test to determine the significance 
of particular comparisons. Two-way analysis of variance was 
used to determine significance in temperature and phago-
cytosis factors. Significance was defined as p-value < 0.05, 
and is presented as * p < 0.05, ** p < 0.01, or **** p < 0.0001.
Results
The monocyte, granulocyte and lymphocyte populations in 
all samples could be clearly identified by flow cytometry in 
the SSC/FSC dot plots. The monocytes are then defined by 
sequential gating on all CD14-positive leukocytes in light 
scatter plots. More than ninety percent of the CD-33 posi-
tive were CD14-positive cells. The CD33 labeling was highly 
specific for the monocytes (Fig. 2).
Temperature-dependent influence in CD33 expression on 
monocyte surface 
The influence of temperature treatment on CD33 expres-
sion of monocytes was investigated as shown in Figure 1. 
Monocytes maintained at 0°C at all stages of preparation 
were defined as the reference levels of expression of CD33. 
Monocytes that were pre-chilled and subsequently 
warmed up and those maintained at 37°C throughout their 
preparation showed a  significantly higher RFI of CD33 
compared to the reference cells maintained at 0°C. There 
was slightly lower, but not signiﬁcantly different expression 
level, for cells cooled at 0°C and subsequently warmed to 
37°C than those cells maintained at 37°C at all stages of 
preparation (Fig. 3A, solid bars). 
These results were independent on the used monoclonal 
antibody against CD33 clone WM53 and P67.6, respectively. 
Figure 2. Gating of the cells, CD14 and CD33 labeled cells. Three groups of cells were identiﬁed based on their forward scatter (FSC) and 
side scatter (SSC). By incubating these cells with Alexa Fluor® 488 anti-CD14 and PerCP/Cy5.5-anti-CD33, monocytes can be identified 
and relative median fluorescence intensity (RFI) was interpreted as positive for CD33 expression from the sample held at 0°C. 
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Figure 3C shows the histograms of four different sample 
types at the investigated temperatures. Isotype staining as 
well as samples without staining provide the same very low 
fluorescence intensity under all conditions. The fluorescence 
intensities of the stained samples (clone WM53 and clone 
P67.6) show no significant differences.
Changes in CD33 expression due to phagocytosis of E. coli 
The ability of monocytes to perform phagocytosis was tested 
for each donor in parallel applying the standard procedure of 
FITC-labeled E. coli as recommended in the PhagotestTM kit 
instructions. Percentages of phagocytizing monocytes and 
Figure 3. Effect of incubation temperature and phagocytosis on CD33 expression on monocytes. Cells were chilled at 0°C, warmed up 
from 0°C to 37°C, or kept throughout at 37°C in the presence of E. coli. A. The bar graphs show the percentage of relative median fluo-
rescence intensity (RFI) of CD33 expression (n = 6). Three populations of monocytes were assessed for expression, cells chilled at 0°C, 
those warmed from 0°C to 37°C, cells held throughout at 37°C without stimulation (solid bar) or with E. coli stimulation (open bar). 
Each bar represents the mean ± SD, and asterisks indicate the significance of differences versus control (* p < 0.1; **** p < 0.0001). B. 
Flow cytometry analysis of CD33 fluorescence intensity (grey area, control; gravy line, monocytes chilled at 0°C; black line, monocytes 
chilled at 0°C, warmed up from 0°C to 37°C; dash line, monocytes held through-out at 37°C). C. Flow cytometry analysis of monocytes 
without staining, stained with two different clones CD33, and isotype control chilled at 0°C, warmed up from 0°C to 37°C and held at 
37°C. No significant differences between the two clones WM53 and P67.6 were found.
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granulocytes and mean fluorescence intensity upon FITC-
labeled E.  coli treatment from healthy donors is given in 
Table 1. After incubation with FITC-labeled E. coli a strong 
increase in both percentages of phagocytosis and mean 
fluorescence intensity was observed, confirming the ability 
of monocytes and granulocytes to perform phagocytosis. 
The fluorescence signal of the phagocytosis activated by 
FITC-labeled E. coli was significantly increased in the FITC-
A channel of the monocyte (Fig. 4A) and granulocyte (Fig. 
4B) population. 
Phagocytosis of E. coli induced a significant increase in 
monocyte expression of CD33 of cells maintained at 37°C, 
or cooled to 0°C and subsequently warmed to 37°C in com-
parison with the reference population of cells held at 0°C 
which did not phagocytose E. coli (Fig. 3B). 
The results clearly show that together with temperature, 
phagocytosis has an augmented effect on the expression of 
CD33. Monocytes held permanently at 37°C and incubated 
with E.  coli up-regulate the expression of CD33 during 
phagocytosis in contrast to cells chilled throughout at 0°C. 
An additional large increment of CD33 expression occurs 
when the cells interact with E. coli (Fig. 3A, open bars).
Internalisation of CD33 during phagocytosis
The influence of phagocytosis was further investigated 
comparing the CD33 staining in samples where the antibody 
was applied after stopping the phagocytosis of E. coli (shock-
cooling at 0°C) with the staining of samples where the an-
tibody was added before phagocytosis activation (warming 
up to 37°C). In parallel to the quantitative determination of 
CD33 expressing monocytes by flow cytometry, we studied 
also the distribution of fluorescence in the cells by CLSM. 
Double staining with FITC-labeled Anti-CD14 and 
PerCP-Cy5-5-A-labeled Anti-CD33 does not allow the use 
of FITC-labeled E.coli. Therefore the ability of monocytes to 
perform phagocytosis was tested for each donor in parallel 
applying the standard procedure of FITC-labeled E.  coli 
(Fig. 5A). Interestingly, by performing double staining, we 
found that in monocytes the CD14 co-localised with CD33. 
It can be seen that the monocytes stained after stopping the 
phagocytosis exhibit a  relatively weak fluorescence signal 
with a distribution mainly on the cell surface (Fig. 5B). In 
contrast, the samples stained before adding E. coli, the fluo-
rescence signal was significantly higher and fluorescence 
was observed by microscopy not only on the surface but 
also inside the cells (Fig. 5C). 
The flow cytometry measurements of the blood samples 
activated for phagocytosis with E.  coli showed a  slightly 
enhanced fluorescence signal in the PerCP-Cy5.5 chan-
nel of the granulocyte population. Fluorescence from 
CD33-positive granulocytes could only be detected when 
anti-CD33 was added before performing phagocytosis in 
Table 1. Percentages of phagocytizing monocytes and granulocytes and mean fluorescence intensity upon 
Fluorescein isothiocyanate (FITC)-labeled E. coli treatment from healthy donors (n = 6)
Type of cells incubated Phagocytic activity (%) Mean fluorescence intensity  in FITC channel
Monocytes
Chilling at 0°C 3.88 ± 3.21 15.35 ± 5.1
Warming up from 0°C to 37°C 84.25 ± 4.97 3764 ± 1323.3
Holding throughout at 37°C 78.63 ± 5.05 3907 ± 1593.4
Granulocytes
Chilling at 0°C 3.55 ± 6.76 19.8 ± 8.58
Warming up from 0°C to 37°C 97 ± 1.54 6241.17 ± 1866.67
Holding throughout at 37°C 95.45 ± 6.23 7027 ± 2775.8
Figure 4. Flow cytometry histograms of the phagocytosis activated 
by Fluorescein isothiocyanate (FITC)-labeled E. coli in the FITC-A 
channel of the monocyte (A) and granulocyte (B) population (grey 
area, chilled at 0°C; black line, chilled at 0°C, warmed up from 0°C 
to 37°C; dash line, held through-out at 37°C).
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contrast to the samples where the staining was performed 
after stopping phagocytosis (Fig. 6B). Since this population 
was also clearly negative for staining with anti-CD33 with-
out E.coli stimulation, a certain non-specific binding of the 
PerCP-Cy5.5-stained CD33 antibody on the opsonized E. coli 
was assumed. To confirm this, we incubated the opsonized 
unlabeled E. coli used for the activation of phagocytosis with 
the PerCP-Cy5.5-anti-CD33 and measured the fluorescence 
signal of the bacteria in the PerCP-Cy5.5 channel with the 
same settings as for the cells (Fig. 6A). The obtained fluo-
rescence signal was similar to the signal measured in the 
PerCP-Cy5.5 for granulocytes stained before phagocytosis 
confirming that this signals is due to the engulfed bacteria 
with some antibody bound on them. In contrast, the fluo-
rescence signal of the monocyte population is at least one 
order of magnitude higher in the same sample (Fig. 6C). 
Discussion
The expression of CD surface antigens may change in 
response to several conditions in varying degrees. The ex-
pression of CD33 has long been recognised as a monocyte 
lineage marker (Terstappen et al. 1990), which helps to detect 
monocytes by flow cytometry. 
Our results have shown that the RFI of CD33-positive 
monocytes which had been first cooled and then re-
warmed was up-regulated compared with those held 
throughout at 0°C, but not significantly different from 
those handled throughout at 37°C. To our knowledge, 
the effect of temperature on the expression levels of CD33 
had not been evaluated yet. It has been previously shown 
that warming of neutrophils from 0 to 37°C (Berger et 
al. 1984), or of neutrophils or monocytes from 4 to 20°C 
(Lundahl et al. 1995; Jämsä et al. 2011), or of monocytes 
from 4 to 37°C (Fearon and Collins 1983; Miller et al. 
1987) as well as maintaining throughout at 37°C (Jämsä 
et al. 2011) strongly up-regulates antigen surfaces, but 
holding throughout at 4°C the changes during storage are 
lower. Our results are in agreement with these findings 
and show that monocytes undergo similar changes. The 
molecular mechanism underlying up-regulation are still 
unclear. One possibility is that the rapid increase in surface 
presentation of CD33 on stimulated monocytes may be 
Figure 5.  Confocal la-
ser scanning microscopy 
(CLSM) images of mono-
cytes phagocytosed E. coli. 
A. Phagocytosis of Fluores-
cein isothiocyanate (FITC)-
labeled E. coli, staining of the 
nucleus of monocytes with 
propidium iodide (fluores-
cence mode and overlay 
micrographs). B. The cells 
were stained at 0°C with 
both Alexa Fluor® 488 anti- 
CD14 and PerCP/Cy5.5 
anti-CD33 after performing 
phagocytosis of non-labeled 
E. coli. C. The cells were first 
incubated with both Alexa 
Fluor® 488 anti- CD14 and 
PerCP/Cy5.5 anti-CD33 for 
30 min at 37°C and then with 
non-labeled E. coli at 37°C, 
which allowed to internal-
ise antibody-bound CD14 
and CD33. The monocytes 
phagocytosed E. coli, which 
results in intracellular fluo-
rescence. Co-localisation of 
CD14 and CD33 staining 
was detected in yellow.
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caused by a translocation of intracellular pool to the cell 
surface (Siddiqui et al. 2017). It has been reported that the 
stimulation of LPS results in increased surface expression 
of CD11b, and CD35 on monocytes, suggesting that these 
rapid changes may be caused by the inflammatory response 
(Furebring et al. 2004). In our study, an increase in CD33 
expression upon E. coli stimulation was found. Therefore, 
up-regulation in CD33 may be involved in the inflamma-
tory response, which has been shown to follow the initial 
systemic pro-inflammatory reaction. CD33 has a  high 
expression on monocyte surface as well as in an internal 
compartment after stimulation of formylated peptides 
(fMLP), a bacterial-derived peptide. This could affect the 
expression of CD33 on the cell surface in response to an in-
flammatory stimulus (Siddiqui et al. 2017). It is also found 
that the high antigen induction on the cell surface upon 
E. coli activation may imply the preformed intracellular 
pool of surface antigen which was rapidly translocated to 
the surface upon activation of these cells (Siddiqui et al. 
2017). However, how LPS-elicited cell signaling regulates 
CD33 surface expression is not clear. 
The results presented here are in contradiction with pre-
vious studies which have published that down-regulation 
of CD33 expression was observed when monocytes were 
activated by LPS (Lajaunias et al. 2005; Siddiqui et al. 
2017). However, LPS is only one component of the gram-
negative bacterial cell wall. Our work was performed with 
opsonized E. coli which presents a cellular pathogen. The 
immune system activation and subsequent responses to 
LPS and E. coli may therefore differ. Another observation, 
in our experiments, CD33 expression increases considerably 
within a very short time after contact with bacteria. This is 
in disagreement with the previously reported results, where 
the incubation time of LPS was up to 2 h (Lajaunias et al. 
2005; Siddiqui et al. 2017). It appears that a  longer time 
period is required to change the CD33 expression profiles 
by LPS. Based on the raising level of CD33 expression after 
exposure to E. coli, revealed significantly altered expression 
levels in monocytes might be a key element for diagnosis 
of septic shock. However, the outcomes should be further 
verified by higher number of blood samples from healthy 
donors and sepsis patients.
It has been shown that the engagement of both surface 
CD33 antigen and anti-CD33 antibody, induces receptor-
mediated endocytosis (Walter et al. 2008b), resulting in 
CD33 internalisation of the antigen/antibody complex into 
the cells (Audran et al. 1995). This process may reduce the 
CD33 presented on the cell surface, but it is continuously 
re-expressed (Van Der Velden et al. 2001). The mecha-
nism of action indicated that the presence of ITIM in the 
intracellular domain of CD33 is critical for the antibody-
mediated CD33 internalisation (Walter et al. 2008a, 2012). 
Intracellular trafficking of CD33 shows that it undergoes 
endocytosis via clathrin-mediated uptake and further traf-
fics to endosomes and processes in lysosomes (Walter et 
al. 2012). Moreover, phosphorylation-dependent ubiqui-
tylation of CD33 decreased the cell surface expression and 
increased the rate of CD33 internalisation (Walter et al. 
2008). As a Siglec family member, CD33 has lectin-like rec-
ognition molecules which is one of the pattern-recognition 
receptors (PRRs) (Vasta 2009). These receptors recognise 
pathogen-associated molecular patterns (PAMPs) from 
microbial pathogens in the first step of phagocytic process. 
An immune response is then triggered when PAMPs are 
recognised. There are some studies mentioned that the 
treatment of monocytes with anti-CD33 antibodies induced 
the production of pro-inflammatory cytokines (IL-1β, IL-8 
and TNF-α) (Lajaunias et al. 2005) including recruited the 
tyrosine phosphatase SHP-1 and SHP-2 (Taylor et al. 1999; 
Paul et al. 2000) and resulted in down-regulated CD64-
Figure 6. Flow cytometry histograms. A. Opsonized E. coli (grey area) and opsonized E. coli incubated with PerCP-Cy5.5-anti-CD33 at 
37°C (black line). Granulocytes (B) and monocytes (C) in samples stained with PerCP-Cy5.5-anti-CD33 after performing phagocytosis 
(grey area), and samples incubated with PerCP-Cy5.5-anti-CD33 before stimulation with non-labelled E. coli at 37°C (black line). The 
y‐axis value varies depending on the number of cell count.
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induced calcium influx (Ulyanova et al. 1999; Paul et al. 
2000). Taken together, our findings may imply that CD33 
could play an associate or even a crucial role in phagocytosis 
of microbial pathogens.
In conclusion, this study shows that the expression of 
CD33 on monocytes is influenced by various stimuli such 
as temperature as well as pathogen. Therefore, excessive 
processing temperatures and the presence of E. coli should 
be taking into account when analysing leukocyte surface 
antigens. Further studies are required to elucidate the par-
ticular mechanisms of CD33 expression and its impact to 
the immune system.
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